Printer Friendly

Parkinson's protection?

Parkinson's protection?

Low doses of a chemical known asMPTP cause brain damage and movement disorders that closely match Parkinson's disease in both humans and monkeys (SN: 3/1/86, p. 132). Robert J. D'Amato of Johns Hopkins University in Baltimore and his colleagues now report that conventional doses of the antimalarial drug chloroquine partially protect monkeys from MPTP-induced symptoms.

"Conceivably, chloroquine or a similardrug could be used to retard the progression of Parkinson's disease in human patients,' they conclude in the May 28 NATURE.

The investigators propose that chloroquineinterferes with the binding of a poisonous MPTP by-product--MPP -- to cells that produce the neurotransmitter dopamine in a small area of the brain known as the substantia nigra. In a previous report, "D'Amato and his co-workers suggested the MPP sticks only to dopamine cells containing the pigment neuromelanin. Nerve terminals that channel MPP out of neuromelanin-bearing dopamine cells in other brain structures are scarce around the substantia nigra.

The proposed neuromelanin connection,while not endorsed by all MPTP researchers, is supported by the new data. Three monkeys were injected with MPTP on four consecutive days, three monkeys received chloroquine for 12 days before and 10 days after MPTP injections, and three monkeys received chloroquine for 24 days before and 10 days after the injections. MPTP alone produced tremors, muscle rigidity, hunched posture and decreased movement within five days. But five of the six chloroquine-treated monkeys displayed significantly fewer parkinsonian symptoms. The five "protected' animals, particularly those given the longer pretreatment, retained more neuromelanin-containing cells in the substantia nigra and showed a much smaller dopamine reduction in two other brain areas implicated in Parkinson's disease, say the researchers.
COPYRIGHT 1987 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1987, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:research on use of chloroquine to retard symptoms of Parkinson's disease
Author:Bower, Bruce
Publication:Science News
Date:Jun 6, 1987
Words:275
Previous Article:Gene search narrows.
Next Article:A parasite with the guts of a burglar.
Topics:


Related Articles
Tracking the root's of Parkinson's disease.
Drug slows Parkinson's progression.
American forces press service (Oct. 3, 2005): Pace issues guidance to help military 'shape the future'.
Progressive MS.
Victory for mobility: MS activists stop a damaging Medicare policy.
What we are doing about symptoms that can't be measured easily.
Stem cells & MS: what the investigators see.
Women aren't "small men": women's health issues are different than men's and need to be addressed specifically.
Alzheimer's marker yields blood test.
Return of the American elm: a beloved classic, long missing from city streets, is starting to make a comeback.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters